My lab aims to understand the basic mechanisms controlling DNA replication in mammalian cells and how disruption of this process leads to genomic instability and cancer.
Our group studies changes in metabolism and metabolic stresses that are caused by oncogene activation and how these stresses lead to tumour suppressive responses.
My research interests focus on mechanisms of disease initiation and maintenance and the identification and validation of novel therapeutic targets in myeloid leukaemias.
Our goal is to identify mechanisms that support haematopoietic stem cell function and understand how the leukaemic stem cells “play” with these mechanisms to thrive.
Our research aims to understand the biology of leukaemia stem cells and identify tricks they use to escape treatments. My group employs multidisciplinary approaches to understand how HSCs chose to self-renew or differentiate and how these cell fate decisions are affected under pathological conditions to generate leukaemic stem cells.
My lab utilises state-of-art multi-omics methodologies to study how protein synthesis is dysregulated in cancer cells, and how this dysregulation contributes to various stages of cancer progression.
Our research is based on exploiting DNA repair defects in cancer for the identification of new personalised therapies. We use compound and siRNA screening to identify new therapeutics for tumours based on their specific DNA repair status.
My lab aims to understand the mechanisms that underlie numerical and structural chromosome aberrations in cancer at a molecular level, which also involves understanding how normal cells replicate and segregate their genomes.
My lab aims to understand the alterations in metabolism that take place in cancer and investigate whether extrinsic factors, such as diet, influence cancer metabolism and disease trajectory. We then want to uncover whether these dependencies can be exploited therapeutically.
My laboratory research explores alternative pre-mRNA splicing in prostate cancer (PCa) biology, and liquid biopsy-derived molecular biomarkers of treatment outcomes.
Our research focuses on how the cytoskeleton of cancer cells regulates transcriptional rewiring during tumour growth and dissemination. We aim to understand how such rewiring affects the tumour microenvironment.
My research focuses on kinase biology and how kinase signalling pathways are hijacked in cancer. We combine computational biology with proteomics and cell biology to uncover novel ways to target these dysregulated networks.
My group studies how RNA-mediated mechanisms, in particular long noncoding RNAs, regulate cell division and how dysregulation of these processes leads to genome instability and cancer.
We work on cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses, in particular focusing on replicating adenovirus and vaccinia virus.
The aim of my research project is to identify and functionally characterise candidate disease genes in familial leukaemia.
My research is focused on combining modulation of the tumour microenvironment with chimeric antigen receptor T cell therapy in order to therapeutically target pancreatic ductal adenocarcinoma.
Using a multi-omics approach, my aim is to systematically reveal the relationship between RNA localisation and protein expression in mammalian cells, and assess how RNA localisation might be dysregulated in cancer cells in order to promote a more malignant phenotype.
My research activity aims to characterise lncRNAs involved in the maintenance of genomic stability and to understand how their dysregulation can lead to cancer development.
My research focuses on the fundamental aspects of leukaemia initiating cell biology in adult acute lymphoblastic leukaemia.
My project focuses on the translation reprogramming in acute myeloid leukaemia upon stresses such as chemotherapy.
Using the fruit fly, Drosophila melanogaster, I aim to dissect the role played by protein phosphatases in regulating the tissue growth controlling Hippo signalling pathway, which has commonly been implicated in cancer development, progression and metastasis.
I am trying to understand how new drugs in combination with carboplatin can help bypass therapy resistance in ovarian cancer.
I use computational biology techniques to understand how normal RNA regulatory mechanisms used in development are hijacked in cancers.
My project looks at the modelling of cancer for improved therapy development. I am carrying out in vivo cancer experiments, with and without modifications of the tumour microenvironment, to examine effects of such treatments on anti-cancer therapy efficacy.
My project looks at the metabolic mechanisms of drug resistance in acute myeloid leukaemia (AML). We look to understand what makes certain cells more vulnerable to AML treatment and how we can use this to improve overall treatment strategies.